|
1
|
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2013
|
2.95
|
|
2
|
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2008
|
2.74
|
|
3
|
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
|
Blood
|
2009
|
2.09
|
|
4
|
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
|
J Clin Oncol
|
2009
|
2.00
|
|
5
|
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
|
Blood
|
2011
|
1.97
|
|
6
|
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
1.91
|
|
7
|
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
|
Blood
|
2009
|
1.84
|
|
8
|
Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study.
|
Blood
|
2011
|
1.64
|
|
9
|
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
|
J Clin Oncol
|
2008
|
1.55
|
|
10
|
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
|
J Clin Oncol
|
2012
|
1.43
|
|
11
|
GSK-3 mediates differentiation and activation of proinflammatory dendritic cells.
|
Blood
|
2006
|
1.34
|
|
12
|
Allogeneic transplantation in lymphoma: current status.
|
Haematologica
|
2007
|
1.25
|
|
13
|
Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation.
|
Blood
|
2010
|
1.24
|
|
14
|
Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease.
|
Blood
|
2007
|
1.24
|
|
15
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2010
|
1.23
|
|
16
|
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
|
Blood
|
2005
|
1.17
|
|
17
|
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2013
|
1.16
|
|
18
|
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
|
Blood
|
2012
|
1.14
|
|
19
|
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma.
|
Cancer
|
2010
|
1.14
|
|
20
|
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity.
|
Biol Blood Marrow Transplant
|
2011
|
1.13
|
|
21
|
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
|
Blood
|
2004
|
1.08
|
|
22
|
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
|
Haematologica
|
2008
|
1.04
|
|
23
|
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.
|
Haematologica
|
2013
|
1.03
|
|
24
|
Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.
|
Ann Hematol
|
2008
|
1.01
|
|
25
|
Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg, Germany.
|
J Clin Microbiol
|
2012
|
1.00
|
|
26
|
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies.
|
Blood Rev
|
2011
|
0.99
|
|
27
|
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.
|
Blood
|
2010
|
0.99
|
|
28
|
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
|
Exp Hematol
|
2012
|
0.98
|
|
29
|
Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.
|
Haematologica
|
2013
|
0.97
|
|
30
|
Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment.
|
Biol Blood Marrow Transplant
|
2012
|
0.96
|
|
31
|
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
|
Blood
|
2009
|
0.94
|
|
32
|
Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
|
J Immunol
|
2003
|
0.93
|
|
33
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
0.91
|
|
34
|
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.
|
Blood
|
2013
|
0.90
|
|
35
|
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
|
Clin Cancer Res
|
2011
|
0.89
|
|
36
|
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
|
Haematologica
|
2010
|
0.88
|
|
37
|
Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.
|
Blood
|
2002
|
0.86
|
|
38
|
Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
|
J Immunol
|
2006
|
0.86
|
|
39
|
Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease.
|
Haematologica
|
2012
|
0.84
|
|
40
|
IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production.
|
Biochem Pharmacol
|
2010
|
0.82
|
|
41
|
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
|
Blood
|
2006
|
0.81
|
|
42
|
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
|
Leuk Lymphoma
|
2013
|
0.81
|
|
43
|
Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?
|
Curr Hematol Malig Rep
|
2012
|
0.81
|
|
44
|
Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
|
Eur J Haematol
|
2014
|
0.81
|
|
45
|
The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma.
|
Curr Opin Oncol
|
2012
|
0.81
|
|
46
|
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
|
Ann Hematol
|
2003
|
0.80
|
|
47
|
CD4+CD25highCD127low regulatory T cells in peripheral blood are not an independent factor for chronic graft-versus-host disease after allogeneic stem cell transplantation.
|
ScientificWorldJournal
|
2012
|
0.79
|
|
48
|
High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.
|
Haematologica
|
2013
|
0.78
|
|
49
|
Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation.
|
Transplantation
|
2015
|
0.78
|
|
50
|
Exercise intensity classification in cancer patients undergoing allogeneic HCT.
|
Med Sci Sports Exerc
|
2015
|
0.77
|
|
51
|
Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.
|
Leuk Lymphoma
|
2013
|
0.77
|
|
52
|
Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study.
|
BMC Cancer
|
2014
|
0.75
|
|
53
|
Reply to C. Fozza.
|
J Clin Oncol
|
2013
|
0.75
|
|
54
|
Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".
|
Haematologica
|
2009
|
0.75
|
|
55
|
Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation.
|
Haematologica
|
2009
|
0.75
|
|
56
|
Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over?
|
Mediterr J Hematol Infect Dis
|
2012
|
0.75
|
|
57
|
Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia.
|
Biol Blood Marrow Transplant
|
2007
|
0.75
|
|
58
|
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
|
Am J Hematol
|
2014
|
0.75
|
|
59
|
Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
60
|
Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects.
|
Ann Hematol
|
2012
|
0.75
|
|
61
|
Autologous transplant of follicular lymphoma in the era of rituximab.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
62
|
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
63
|
Imatinib-supplemented myeloablative total-body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia.
|
Eur J Haematol
|
2014
|
0.75
|
|
64
|
Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
|
Eur J Haematol
|
2005
|
0.75
|
|
65
|
Impact of HSCT Conditioning and Glucocorticoid Dose on Exercise Adherence and Response.
|
Med Sci Sports Exerc
|
2017
|
0.75
|